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Abstract 
Loss of articular cartilage through injury or disease presents major clinical challenges 
also because cartilage has very poor regenerative capacity, giving rise to the development 
of biological approaches. As autologous blood product, platelet-rich plasma (PRP) 
provides a promising alternative to surgery by promoting safe and natural healing. Here 
we tested the possibility that PRP might be effective as an anti-inflammatory agent, 
providing an attractive basis for regeneration of articular cartilage, and two principal 
observations were done. First, activated PRP in chondrocytes reduced the transactivating 
activity of NF-kB, critical regulator of the inflammatory process, and decreased the 
expression of COX2 and CXCR4 target genes. By analyzing a panel of cytokines with 
different biological significance, in activated PRP we observed increases in hepatocyte 
growth factor (HGF), interleukin-4 and tumor necrosis factor-α (TNF-α). HGF and TNF-
α, by disrupting NF-kB-transactivating activity, were important for the anti-inflammatory 
function of activated PRP. The key molecular mechanisms involved in PRP-inhibitory 
effects on NF-kB activity were for HGF the enhanced cellular IkBα expression, that 
contributed to NF-kB-p65 subunit retention in the cytosol and nucleo-cytoplasmic 
shuttling, and for TNF-α the p50/50 DNA-binding causing inhibition of target-gene 
expression. Second, activated PRP in U937-monocytic cells reduced chemotaxis by 
inhibiting chemokine transactivation and CXCR4-receptor expression, thus possibly 
controlling local inflammation in cartilage. In conclusion, activated PRP is a promising 
biological therapeutic agent, as a scaffold in micro-invasive articular cartilage 
regeneration, not only for its content of proliferative/differentiative growth factors, but 
also for the presence of anti-inflammatory agents including HGF. 
Introduction 
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Clinical evidence suggests that platelet concentrate could have beneficial therapeutic 
effects on hard and soft tissue healing, due to the content of growth factors (GFs) stored 
in the platelets (Lacoste et al., 2003). As autologous blood product, platelet-rich plasma 
(PRP) provides a promising alternative to surgery by promoting safe and natural healing 
(Sampson et al., 2008). Recently, we have learned more about specific GFs with a crucial 
role in healing process. Various GFs are present in PRP: alpha granules are storage units 
within platelets, which contain pre-packaged GFs in an inactive form. These include 
platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β1, vascular 
endothelial growth factor (VEGF) and epidermal growth factor (EGF).  
Over the last decade, PRP has found clinical application for the wound healing 
process in the field of periodontal and oral surgeries, cartilage repair and plastic surgery, 
and in chronic non-healing musculoskeletal and tendon injuries and cartilage 
degeneration (Banfi et al., 2006; El-Sharkawy et al., 2007; Sampson et al., 2008; Vardar-
Sengul et al., 2009; Cervelli et al., 2009; Pallua et al., 2010; Wu et al., 2009).  
Some recent clinical reports suggest that more rapid epithelization, denser and 
more mature bone with better organized trabeculae, and greater bone regeneration 
occurred when PRP was added to xenograft and synthetic graft materials (Hanna et al., 
2004). As a rich source of GFs, PRP is used in tissue engineering to increase the levels of 
GFs from intracellular stores potentially maximizing the benefit, as in the case of dental 
implants and joint space (Tischler, 2002; Sampson et al., 2008). 
A lack of post-surgical inflammation is a consistent anecdotal observation 
associated with the use of PRP (El-Sharkawy et al., 2007). An inflammatory response of 
appropriate magnitude and timing is crucial for tissue repair and homeostasis (Oberyszyn, 
2007). It is imperative, therefore, to develop a novel therapy that could effectively control 
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inflammation without significant adverse effects for patient safety. Clinical applications 
and molecular studies with PRP deal with GFs that regulate cellular events such as 
proliferation, differentiation, chemotaxis and morphogenesis of cells, tissues and organs. 
However, few studies consider the presence and the possible anti-inflammatory role of 
cytokines in the PRP after activation with thrombin. Calcium chloride and thrombin may 
be added to provide a gel matrix for the PRP to adhere to, potentially maximizing the 
benefit in the case of cartilage repair (Wu et al., 2009). The mechanisms by which 
thrombin activates platelets and other cells to release various mediators such as GFs have 
been reviewed (Puri, 1998). 
The aim of the present paper was to understand the anti-inflammatory role of 
cytokines in PRP activated by calcium chloride and thrombin on human chondrocytes, 
and the molecular mechanism(s) involved. The principal transcription factor regulating 
the inflammatory process is NF-kB, a homo-/hetero-dimer in which subunit association 
has different biological significances (Perkins, 2006; Ghosh and Hayden, 2008). Dimers 
containing p65 show transactivating activity. Proteasomal degradation of phosphorylated 
IkB plays a role in nuclear translocation of p65 subunit of NF-kB, regulating 
transactivating activity, but constitutive NF-kB activation is not always associated with 
increased degradation of IkB. NF-kB may be activated by different direct or indirect 
phosphorylation (Perkins, 2006,) as well as acetylation (Bendinelli et al., 2009). IkBα, 
considered a gene target of NF-kB (Gao et al., 2005), negatively controls transcription 
factor activity by nucleo-cytoplasmic shuttling of p65 (Arenzana-Seisdedos et al., 1997; 
Ghosh and Hayden, 2008).  
To this purpose, we examined the effects of Hepatocyte growth factor (HGF) and 
Tumor necrosis factor-α (TNF-α), found augmented in the activated PRP, on the 
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transactivating activity of NF-kB, on the involvement of IkBα in p65 translocation and on 
the role of the inhibitory p50/50 homodimer in target-gene expression. The molecular 
mechanisms negatively regulating NF-kB activity have never been investigated in 
chondrocytes exposed to activated PRP. HGF exerts multi-target anti-inflammatory 
actions (Gong, 2008), and TNF-α elicits a variety of responses, depending on the cellular 
context (Zetoune et al., 2001). The modulation of NF-kB-transactivating activity by 
autologous-activated PRP in chondrocytes might help to suppress inflammation by 
inhibiting the expression of pro-inflammatory genes, such as cyclooxygenase-2 (COX-2)  
(Ulivi et al., 2008). Another mechanism played by activated PRP, involved in limiting 
local inflammation, seemed to be the prevention of chemotaxis of monocyte-like cells by 
reducing the expression of chemokine-receptor CXCR4 and the transactivation of 
chemokines,  monocyte chemotactic protein-1 (MCP-1) and RANTES, target genes of 
NF-kB (Nam, 2006). 
 
Materials and Methods 
Materials  
Recombinant human HGF, interleukin (IL)-4, TNF-α, EGF, VEGF, TGF-β1 and IL-1β as 
well as human HGF, TGF-β1, PDGF Quantikine immunoassay kits, anti-human CXCR-
4-phycoerythrin (PE) (clone 12G5) and IgG2A isotype control-PE antibodies were from 
R&D System (Abingdon, UK). Thrombin-JMI was from King Pharmaceuticals (Bristol, 
UK). Anti-IkBα (C21), anti-NF-kB p65 (A) and anti-actin antibodies were from Santa 
Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488 and 586 secondary antibodies 
were from Molecular Probes (Eugene, OR). The gene reporter plasmids NFkBLuc and 
IkBαLuc were kindly provided by Dr. M. Hung (Anderson Cancer Center, Huston, TX) 
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and Dr. J. Ye (Luisiana State University System, Baton Rouge, LA); the (-
1432/+59)COX-2 gene reporter (COX2Luc) was kindly provided from Dr. S. Wilkinson 
(Vanderbilt University, Nashville, TN); the original gene reporter pCXCR4(-
2632/+86)Luc (kindly provided as pGL2 basic construct by Dr. A. J. Caruz, Universidad 
de Jaen, Madrid, Spain) was subcloned in the pGL2-enhancer (Maroni et al, 2007); the 
A20 gene-reporter construct A20-Luc, containing the proximal region of the promoter, 
was kindly provided by Dr. R. Dikstein (The Weizmann Institute of Science, Rehovot, 
Israel). MCP-1 (D26087) gene reporter in pGL3-basic was form Dr. I. Morita (Tokyo 
Madical and Dental University, Tokio, Japan). RANTES gene reporter, containing the 
promoter spanning -974 to +55, was prepared in pGL3-basic (Pazdrak et al., 2002). The 
expression vectors for NF-kB subunits p50 (pCMV-p50) and p65 (pCMV-p65) were 
kindly provided by Dr. W.C. Greene (University of California, San Francisco, CA). NK4 
to be used in vitro, was a gift of Dr. T. Nakamura (University of Osaka, Osaka, Japan).  
Cell cultures 
The immortalized line of normal human articular chondrocytes (Ibpva55), established by 
Dr. A. Facchini (Istituti Ortopedici Rizzoli, Bologna, Italy), was used. This line is an 
ideal model for cartilage research since it represents a permanent and abundant source of 
cells expressing the physiological characteristics of original tissue (Grigolo et al., 2002). 
The Ibpva55 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
25 mM HEPES buffer, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml 
gentamicin, supplemented with 20% foetal bovine serum. The medium was changed 
twice a week and, at confluence, the cells were trypsinized and expanded in culture 
(Roseti et al., 2007). Human monocytic tumor cell line  U937 was kindly provided by Dr. 
A. Pessina (University of Milan, Italy). U937 cells were cultured in RPMI-1640 medium 
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containing 100 U/ml penicillin, 100 µg/ml streptomycin supplemented with 10% foetal 
bovine serum. All the cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2. 
Preparation and activation of PRP 
Whole-blood samples were collected from 18 healthy donors, undergoing reconstruction 
of the anterior cruciate ligament, who provided their informed consent. The procedures 
followed were in accordance with Helsinki Declaration. PRP was obtained using the 
platelet concentrate collector system GPS II (Biomet, Bridgen, Wales, UK) (Banfi et al., 
2006). This system allows the production of PRP with 8-fold concentration of platelets. 
PRP was activated using 142.8 U/ml thrombin and 14.3 mg/ml CaCl2·2H2O, conditions 
typically used for clinical application (condition A, reported by Roussy et al., 2007). PRP 
aliquots were activated for 1 and 24 h at 37°C. Samples were centrifuged for 10 min at 
4,000 x g, and PRP supernatants were harvested. Cell count in PRP was made on the 
smears stained with Giemsa. 
Determination of cytokine concentrations in PRP 
HGF, PDGF and TGF-β1 were measured in 50 µl of non activated and activated PRP, 
using Quantikine Immunoassay kits and following manifacturer’s protocol. The cytokines 
IL-4, -6, -8, -10, VEGF, interferon-(IFN-)γ, TNF-α, IL-1α, IL-1β, MCP-1 and EGF were 
quantified in non activated and activated PRP by a biochip array analyzer (Evidence, 
Randox Laboratories Ltd, Crumlin, UK). The assay of all 11 molecules was performed 
simultaneously, using just one assay diluent, one panel-specific conjugate solution and 
one signal reagent, in 50 µl of non activated PRP and in 5 µl (diluted 1:10 to obtain a 
final volume of 50 µl) of activated PRP. The biochip used consists of a 9.9-mm solid 
substrate on which discrete test regions have been constructed. The binding ligands 
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(antibodies) are attached to predefined sites on the chemically modified surface of the 
biochip. After a simple enzyme-linked immunoadsorbent assay procedure, the 
chemiluminescent signals generated at each spot on the array are imaged. The light signal 
is captured by a charge-coupled device camera as part of an imaging station, and 
converted by an image-processing software, to provide results compared with calibration 
curves for each location on the biochip. 
Plasmids and cell transfection 
For gene reporter assays, NFkBLuc containing three NF-kB consensus sequences, 
IkBαLuc driven by IkBα promoter, COX-2Luc, CXCR4Luc, A20Luc, MCP-1Luc or 
RANTESLuc promoter construct was used. Adherent (Ibpva55) or suspension (U937) 
cells, seeded in 24-multiwell plates, were transfected using Fugene 6 (Roche, Basel, 
Switzerland) (Bendinelli et al., 2009). All these cells were incubated with DNA/Fugene 
mixture containing 200 ng of each gene reporter per well and 40 ng of pRL-TK (Renilla 
luciferase) for normalization. Some cells were transfected with 200 ng of the expression 
vectors for p50 and p65,  together with COX-2Luc or A20Luc, or were exposed to 20 
ng/ml TNF-α under starvation. Some cells, transfected with the gene reporter, were 
starved for 16 h and then treated for 24 h with two different volumes (250 or 800 µl) of 
non activated or activated PRP, or with recombinant human cytokines: HGF (40 ng/ml) 
(Desiderio et al., 1998), IL-4 (20 ng/ml) (Legitimo et al., 2007), TNF-α (20 ng/ml) 
(Psarra et al., 2009), EGF (20 ng/ml) (Kim et al., 2009), VEGF (10 ng/ml) (Han et al., 
2009), or TGF-β1 (5 ng/ml) (Hiraga et al., 2006).  Samples (250 µl) of activated PRP 
were also tested in the presence of 110 nM NK4 (Kishi et al., 2009). Firefly/Renilla 
luciferase activity ratios were calculated by the software.   
Western blot assay 
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Total extracts (100 µg of proteins) from Ibpva55 cells exposed or not to HGF were 
examined by Western blot (Bendinelli et al., 2009). β-actin was used for normalization of 
protein loading. Densitometric analysis was performed after reaction with ECL 
chemiluminescence kit (GE Healthcare, Milan, Italy). 
Immunofluorescence 
Ibpva55 cells were seeded (8 x 104 per well) on sterile coverslips, previously placed in 24 
multiwell plates, and allowed to attach as described (Bendinelli et al., 2009). After 
starvation for 16 h and treatment with HGF (40 ng/ml for 3 h) or IL-1β (10 ng/ml for 15 
min) (Wang et al., 2005), the cells were fixed with 4% paraformaldehyde solution. Slides 
were then incubated with anti-p65 antibody (1:50), rinsed and probed with the secondary 
fluorescent antibody Alexa Fluor 568 (1:800). After washing and treatment with 
paraformaldehyde, reaction with anti-IkBα antibody (1:50) was performed, followed by 
the secondary fluorescent antibody Alexa Fluor 488. The cells were examined with a 
fluorescent microscope (Eclipse 80i, Nikon Instruments, Florence, Italy), and the images 
were collected at X400 magnification. 
NF-kB-DNA binding activity assay 
Protein nuclear extracts were prepared from chondrocytes exposed or not to TNF-α (20 
ng/ml for 30 min) with the kit from Active Motif (Carlsbad, CA), and used for binding of 
NF-kB-p50 and p65 subunits to the NF-kB consensus sequence 5’-GGGACTTTCC-3’. 
The measurements were performed with the ELISA-based TransAM-NF-kB kit, 
according to manufacturer’s instruction. 
Flow cytometry analysis of U937 cells for  CXCR4 expression  
Starved U937 cells (1.5 X 106 cells/well in 6-multiwell plates) were treated overnight 
with PRP activated for 1h, and were analyzed for CXCR4 expression by flow cytometry 
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(CyFlow, PAS Partec, Münster, Germany) using anti-human CXCR-4-PE antibody 
according to the manufacturer’s protocol. Isotype-matched IgG2A-PE was used as control. 
Chemotaxis assay 
Chemotaxis was examined by measuring the migration of U937 cells through a porous 
membrane (8.0 µm pore size), in response to the CXCR4-agonist CXCL12 and activated 
PRP, in a  96-well microchamber (NeuroProbe ChemoTx, NeuroProbe Inc. Gaithersburg, 
MD). In the lower chamber (volume of 300µl), we placed RPMI-1640 without serum 
supplemented with 100 ng/ml of CXCL12 (Moriuchi et al., 1997) and, when indicated, 
250 µl of  PRP activated for 1h. Controls without CXCL12 were prepared. Then, 25 µl of 
U937 cells, suspended to a final concentration of 2 x 106 cells/ml in RPMI without 
serum, were added on the top of the filter for each well. The chambers were incubated for 
2 h at 37°C in a humidified incubator. The cells on the upper layer of the membrane were 
removed with a cotton swab, washing with PBS, and those migrated, adhering to the 
under side of the filter, were fixed with methanol, stained with Diff-Quick (Dade Behring 
Inc., Newark, DE), and manually counted under microscope (Eclipse 80i, Nikon 
Instruments, Florence, Italy) at  X400 magnification.  
Statistical analysis 
All the data were analyzed by analysis of variance, with P<0.05 considered significant. 
 
Results 
Balance between cytokines with anti-inflammatory significance and pro-
inflammatory/proliferative cytokines  in activated PRP 
Thrombin has been shown to be a potent agent for platelet aggregation and induction of 
GF and cytokine release (Lacoste et al., 2003). In the present experiments, we activated 
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PRP with calcium chloride and thrombin, at doses used for clinical applications. PRP 
activation was performed for short (1 h) and long (24 h) times (Roussy et al., 2007). On 
average, 8-fold increase in platelet concentration was achieved with GPSII System. 
In experiments performed by immunoassay, HGF, TGF-β1 and PDGF 
concentrations were evaluated under our experimental conditions (Table 1). HGF was 
present in non activated PRP and increased after activation with thrombin of about 2-4-
fold at 1 h and 24 h. It is worth noting that in non activated and activated PRP, HGF had 
concentrations in the range of ng/ml that might be considered fairly elevated. Both in 1 h- 
and 24 h-activated PRP, TGF-β1 and PDGF  concentrations increased of about 2.5- and 
3.5-fold, respectively, when compared with non activated PRP. Further, we observed that 
monocytes and neutrophils were present in PRP, together with platelets, but they showed 
a very lower concentration than platelets (Table 1). This finding was consistent with 
possible HGF production by monocytes and neutrophils (Koyama et al., 2003; Toyama et 
al., 2005; Gong, 2008), even if the low concentration of monocytes and neutrophils in our 
PRP samples made difficult to separate them and to evaluate the HGF release.  
Then, we measured the concentrations of a panel of cytokines with different 
biological significance (El-Sharkawy et al., 2007; Sampson et al., 2008; Seruga et al., 
2008)  (Fig. 1). The activation of PRP for 1 h and 24 h caused remarkable increases in the 
anti-inflammatory cytokines: IL-4 and IL-10 augmented 11- and 5-fold, respectively. The 
pro-inflammatory cytokine levels were very low: IL-1β was the most represented and 
showed a slight increase in the activated PRP, in agreement with the literature (Roussy et 
al., 2007). Chemotactic factor concentrations were elevated, but did not change in 
activated PRP. TNF-α increased 2-3-fold at 1 h and 24 h after activation of PRP. The 
concentration of TNF-α was, however, 1 x 102 -   to 1 x 103 –fold less that those of HGF 
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and  TGF-β1.  VEGF and EGF were well represented in non activated PRP, increasing 
after thrombin exposure, never reaching however the level of HGF.  
Inhibition of NF-kB transactivatig activity by activated PRP, and role of the various 
cytokines  
To evaluate the possible anti-inflammatory function of PRP, we studied NF-kB 
transactivation using a gene-reporter construct, driven by three NF-kB consensus 
sequences, that was transiently transfected in chondrocytes (Fig. 2A). The measure of 
luciferase activity, in the case of a gene reporter driven by multiple consensus sequences 
for a transcription factor, gives a real proof of transcription factor function on gene target 
expression. We tested two different volumes of non activated and activated PRP. 250 µl 
of activated PRP reduced of about 60% NF-kB transactivation. 800 µl of activated PRP 
similarly caused 70% decrease of luciferase activity. The inhibitory effect of 250 µl of 
activated PRP on NF-kB transactivation was largely prevented by concomitant treatment 
of the chondrocytes with NK4, a specific competitive inhibitor of HGF (Kishi et al., 
2009). 
 To clarify which of the GFs and cytokines, increased in activated PRP, were 
involved in the diminution of NF-kB transactivation, HGF, IL-4, TNF-α, VEGF and EGF 
were tested on NFkBLuc activity (Fig. 2B). HGF alone or in the presence of IL-4 reduced 
(65%) luciferase activity. IL-4 and TNF-α alone gave inhibitory effects of about 40%. 
VEGF and EGF were ineffective on NF-kB transactivation under our experimental 
conditions. 
 The effect  of activated PRP in chondrocytes was examined on two NF-kB-target 
genes, COX-2 and CXCR4 expressed in chondrocytes (Maroni et al., 2007; Lee et al., 
2008; Ulivi et al., 2008; Haringman et al., 2004), by measuring the luciferase activity of 
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the gene reporters. Activated PRP reduced of about 50% the COX-2 and CXCR4 
luciferase activities (Fig. 2C). 
IkBα is involved in the inhibitory effect of HGF on NF-kB transactivation in 
chondrocytes 
Some molecular mechanism(s) responsible for NF-kB inhibition by HGF were examined 
by considering the functional role of IkBα in chondrocytes. To this purpose, the 
luciferase activity of the gene reporter driven by IkBα promoter was measured to evaluate 
the IkBα gene transcription in chondrocytes. HGF increased (about 2-fold) IkBα 
luciferase activity (Fig. 3A). Consistently, at 6 and 24 h after HGF treatment IkBα protein 
level increased (2- 2.5-fold) as shown by Western Blot (Fig. 3B). 
 The intracellular distribution of endogenous IkBα and p65 after HGF treatment 
was evaluated by immunofluorescence. As shown in Figure 3C, in starved cells p65 
signal was cytoplasmic, and IkBα signal was present in the cytosol and slightly in the 
nuclei. After HGF exposure, p65 remained in the cytosol and IkBα increased both in the 
cytosol and nuclei. As shown in merge III, p65 and IkBα signals strongly co-localized in 
the cytosol after HGF treatment and IkBα was the only signal in nuclei, index of new 
synthesis (Hochrainer et al., 2007). These molecular events might be related to NF-kB 
activity inhibition. To demonstrate that specific stimuli activating NF-kB caused indeed 
p65 translocation to the nucleus, we treated starved chondrocytes with IL-1β. After 
treatment with IL-1β, p65 localized prevalently in nuclei while IkBα localization was 
unchanged, compared to starvation (Fig. 3C). 
Role of NF-kB-p50 subunit in the TNF-α response in chondrocytes 
To clarify the molecular mechanism responsible for inhibition of NF-kB transactivation 
by TNF-α, we used different approaches to study the possible involvement of the p50 
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inhibitory subunit. It is known that p50 homodimers, that lack transactivation domains, 
generally repress NF-kB-dependent gene expression (Schmitz and Baeuerle, 1991), and 
p50/50 DNA binding is activated by TNF-α in a pro-inflammatory milieu (Yue et al., 
2008). 
 First, we evaluated the effect of TNF-α treatment on DNA binding of NF-kB-p50 
or NF-kB-p65 subunit. The oligonucleotide used for the binding, furnished by the 
commercially available kit, has a sequence “GGGACTTTCC”, corresponding to the core 
and the flanking region of NF-kB consensus sequence (-223 to -214) present in COX-2 
promoter (Chen et al., 2005). As shown in Figure 4A, TNF-α treatment increased of 
about 6-fold p50-DNA binding, indicating a possible inhibitory role of the homodimer in 
chondrocytes. p65-DNA binding was only 2-fold higher in TNF-α treated than in starved 
cells, probably because p50/50 may displace activating p50/65 heterodimers leading to 
transcriptional repression (Yue et al., 2008). 
 Then, chondrocytes were transfected with the construct containing the promoter 
of COX-2 or A20, TNF-α target genes regulated by NF-kB (Lee et al., 2008, Li and Lin, 
2008). Both TNF-α treatment and p50-expression vector co-transfection inhibited COX-2 
and A20 luciferase activities, while the co-transfection with p50 and p65 was ineffective 
(Fig. 4B).  
Endogenous CXCR4 expression in U937 cells was reduced by activated PRP 
We hypothesized that activated PRP might control local inflammation in regenerating 
cartilage not only acting on chondrocyte gene expression, but also by controlling 
chemotaxis of inflammatory cells. The couple CXCL12/CXCR4 is involved in 
maintaining homeostatic leukocyte traffic and in the recruitment of  monocytes and 
neutrophils at the sites of inflammation (Haringman et al., 2004). U937 cells are 
 15
considered a model for endogenous expression of CXCR4 receptor (Zabel et al., 2009; 
Moriuchi et al., 1997). In response to overnight exposure to activated PRP, in U937 cells 
the endogenous expression of CXCR4 was abolished (Fig. 5). This finding is consistent 
with reduced CXCR4 transactivation observed in chondrocytes exposed to activated PRP, 
as shown in Figure 2. 
Inhibition of CXCL12-induced U937-cell migration by activated PRP 
We used the U937-human monocytic tumor cells to evaluate the possible inhibitory role 
of PRP on chemotaxis of inflammatory cells (Fig. 6).  
 As shown in Figure 6A, the migration of U937 cells towards CXCL12, the 
specific CXCR4 ligand, increased 5.5-fold compared to control cells. The latter showed 
spontaneous migration, and the mean count for ten fields was 40 cells. Migration towards 
CXCL12 was inhibited by activated PRP from patient 1 (78 %) and from patient 2 (62 
%). Representative images of the migrated cells under the different treatments are shown. 
 Chemokines are a family of pro-inflammatory cytokines that can stimulate the 
target-cell specific directional migration of leukocytes: MCP-1 and RANTES are 
produced by monocytes and drive monocyte/macrophage chamotaxis (Julkunen et al., 
2001). We transfected MCP-1 and RANTES gene reporters in U937 cells, and the 
response to activated PRP was studied. As shown in Figure 6B, after exposure to 
activated PRP the MCP-1 and RANTES luciferase activities were reduced of bout 60 %. 
To evaluate the possible role of the cytokines present in activated PRP on chemokine 
expression, the response to TNF-α (20 ng/ml) and TGF-β1 (5 ng/ml) alone or in 
combination was examined. While TNF-α alone activated MCP-1Luc and RANTESLuc 
(3.1-fold and 2.3-fold, respectively), TGF-β1 co-treatment largely prevented these 
activations. 
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Discussion 
In PRP activated by thrombin, at doses used for clinical applications, we found an 
enhanced content of HGF, IL-4, TNF-α and TGF-β1. We propose that these cytokines 
participated in the anti-inflammatory effect of activated PRP with various mechanisms: 
HGF and TNF-α by reducing NF-kB transactivating activity and target-gene (COX-2 and 
CXCR4) expression in chondrocytes, while TGF-β1 counteracted TNF-α effect on 
chemokine transactivation preventing monocyte chemotaxis. We observed increases in 
other GFs such as VEGF and EGF, known to regulate angiogenesis like HGF, and also 
cell differentiation, re-epithelialization and collagenase activity. Enhancement of PDGF 
might promote granulation tissue formation (Desiderio, 2007; Sampson et al., 2008; 
Gong, 2008). Pro-inflammatory cytokines were very low in activated PRP. Altogether, 
these properties of activated PRP, i.e. the control of inflammation and 
proliferation/differentiation, may have a central role in tissue regeneration (Oberyszyn, 
2007). 
 Activated platelets release TGF-β1, PDGF and VEGF from alpha granules 
(Roussy et al., 2007), contaminating monocytes and neutrophils are supposed to produce 
HGF, and leukocytes have an impact on thrombin-induced IL-1β synthesis by platelets 
(Pillitteri et al., 2007).  
 Articular cartilage, a specialized connective tissue that bears load and reduces 
friction across moving joints, has limited regenerative capacity. The treatment of various 
cartilagineous lesions remains a challenge to clinicians (Wu et al., 2009). Hydrogel, 
formed by PRP in the presence of thrombin, provides a three-dimensional support to cell 
growth, and can be used as a scaffold acting as a cell carrier for autologous chondrocyte 
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implantation into a defective site of articular cartilage (Brehm et al., 2006; Wu et al., 
2009). Moreover, autologous PRP is less immunogenic and more biocompatible, than 
other biomaterials, and is a source of active biological factors, such as HGF. For these 
reasons we thought interesting to use human chondrocytes as a model. 
 HGF seemed to exert the anti-inflammatory effect on human chondrocytes 
through inhibition of NF-kB transactivating activity. Most importantly, HGF was the 
principal cytokine of PRP playing this anti-inflammatory role, because blockade of its 
function with the specific competitive inhibitor NK4 almost completely prevented the 
inhibitory effect of activated PRP on NF-kB transactivating activity. NK4 is a truncated 
form of HGF that competes for the binding to Met receptor (Kishi et al., 2009). Our 
present observations add new data on the role of HGF as potent therapeutic anti-
inflammatory agent. It has been reported that HGF inhibits renal inflammation in vivo, 
preventing inflammatory cell infiltration, through disruption of NF-kB activity 
(Giannopoulou et al., 2008). 
The key molecular mechanism(s) underlying NF-kB inhibitory effect was that 
HGF impaired p65 translocation to the nucleus, that is necessary for NF-kB 
transactivating activity and gene expression (Perkins, 2006; Ghosh and Hayden, 2008). 
Under basal conditions, p65 is prevalently localized in the cytosol and p50 is 
constitutively present in the nuclei (Bendinelli et al., 2009). In response to HGF, IkBα 
expression increased and possibly contributed to maintain p65 in the cytosol, consistent 
with the anti-inflammatory role played by IkBα (Wang et al., 2005; Gong, 2008). In 
addition, when IkBα is increased in the nucleus, as occurred in our experimental 
conditions after HGF exposure, it might inhibit the interaction of NF-kB with DNA 
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promoting the export of p65 from the nucleus to the cytoplasm (Arenzana-Seisdedos et 
al., 1997; Ghosh and Hayden, 2008). 
 The control of the activity of IkBα promoter is complex. Normally, IkBα is 
considered a NF-kB-target gene (Gao et al., 2005). However, other transcription factors 
are probably involved in the up-regulation of IkBα gene expression, and c-Rel C-terminal 
may regulate the mRNA level of IkBα by post-transcriptional mechanisms increasing 
stabilization (Ito et al., 1994; Iwai et al., 2005). In addition, co-activators and co-
repressors are simultaneously recruited to the promoter of IkBα. Although different co-
repressor complexes, such as SMRT-HDAC1 and NCoR-HDAC3, can inhibit NF-kB 
activity, it seems that they act at different time-points along IkBα transcription induced 
by NF-kB (Gao et al., 2005). 
 IL-4 and TNF-α might participate in the control of the inflammatory process 
exerted by HGF in chondrocytes. Because HGF alone or in combination with IL-4, 
similarly inhibited NF-kB transactivating activity, we suggest that the two cytokines 
shared the signaling pathway activated downstream.  
 TNF-α was involved in different molecular and cellular events responsible for the 
control of local inflammatory response, possibly facilitating cartilage healing. First, TNF-
α exerted  inhibitory effect on COX-2- promoter transactivating activity in chondrocytes, 
as occurred after exposure to activated PRP. COX-2 is a key pro-inflammatory gene, 
producing prostaglandin mediators, and is a NF-kB-target gene in several cell types 
including chondrocytes (Alaaeddine et al., 1999; Ulivi et al., 2008; Lee et al., 2008). An 
important molecular mechanism, accounting for reduction of gene transcription in 
chondrocytes exposed to TNF-α, seemed to be p50-homodimer formation and its 
enhanced DNA binding, responsible for the inhibition of NF-kB activity. The TNF-α-
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induced reduction of A20 expression involved the same mechanism. A20 is a well known 
inhibitor of NF-kB activity, turning-off the TNF-α-activated signal (Li and Lin, 2008). In 
agreement with the decreased NF-kB transactivation by TNF-α in chondrocytes, we 
observed a remarkable diminution of A20-promoter activity that is dependent on NF-kB-
activity.  
 Consistent with our present data, TNF-α decreases the expression of target genes 
of NF-kB by forming homodimers p50/50 in a pro-inflammatory milieu due to activated 
macrophages that produce TNF-α (Yue et al., 2008). The different responses and the 
genes regulated by TNF-α may depend on the cellular context, involving specific 
regulatory mechanisms (Zetoune et al., 2001). We cannot exclude an interaction  HGF-
TNF-α in chondrocytes exposed to activated PRP, because it is known that HGF 
attenuates TNF-α-induced phosphorylation of NF-kB-p65 subunit and IkBα, and reduces 
NF-kB-mediated transcriptional activity (Gong et al., 2006). Thus, HGF and TNF-α 
might contribute to inhibit pro-inflammatory mediators. 
 Second, activated PRP inhibited monocyte-like cell chemotaxis, possibly by 
reducing the expression of the chemokine-receptor CXCR4, and of the chemokines MCP-
1 and RANTES, all target genes of NF-kB (Nam, 2006; Maroni et al., 2007). A possible 
explanation of the latter inhibitory effect of activated PRP might be that TGF-β1 
counteracted the TNF-α dependent stimulation of chemokine transactivating activity. 
Consistently, negative regulation of mucosal inflammation by TGF-β1 occurs through 
blockade of TNF-α effect  (Stadnicki et al., 2009). 
 In conclusion, the data herein reported clarify new aspects related to an anti-
inflammatory role of activated PRP due to the presence of HGF. These findings are 
relevant for regenerative medicine because tissue regeneration, including that of cartilage 
 20
does not occur without the control of inflammation. Also for periodontal regeneration, 
PRP facilitates healing by controlling the local inflammatory response (El-Sharkawy et 
al., 2007). In PRP activated by thrombin at clinical doses not only reparative GFs but also 
HGF, together with IL-4, TNF-α and TGF-β1, might explain the validity of its 
application in different clinical fields including micro-invasive articular cartilage 
regeneration. Our observation that CXCR4 expression was reduced in chondrocytes 
exposed to activated PRP might have a clinical significance in inflamed synovia, for 
example by reducing matrix-metalloproteinase secretion, that are cartilage-matrix 
degrading enzymes. 
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Legends to figures 
 
Fig. 1. Mean concentrations of a panel of cytokines and growth factors in PRP from 9 
patients. The data are the mean ± S.E. of experiments repeated three times.   Non-
activated PRP; PRP activated for     1 h  and     24 h. *P<0.05, **P<0.005 and 
***P<0.001 vs. non-activated PRP.  
 
Fig. 2. Activated PRP was responsible for inhibition of NF-kB-transactivating activity, as 
well as of CXCR4 and COX-2 target genes. A: Chondrocytes transfected with the 
construct containing the NFkB multimer, were treated with non-activated (n.a.) PRP or 
activated (a.) PRP, in the presence or the absence of 110 nM NK4. The histograms 
indicate the absolute values for Firefly/Renilla luciferase activity ratios. Columns, mean 
of five independent experiments (5 patients) performed in triplicate; bars, S.E. *P<0.05 
and **P<0.005 vs. n.a. PRP (250 µl); ∆P<0.05 vs. n.a. PRP (800 µl); ○ P<0.05 vs. a. PRP 
(250 µl). B: Chondrocytes transfected with the construct containing the NFkB multimer, 
were treated with the various cytokines and growth factors shown. The histograms 
indicate the absolute values for Firefly/Renilla luciferase activity ratios. Columns, mean 
of three independent experiments performed in triplicate; bars, S.E. *P<0.05 and 
**P<0.005 vs. starved (st) cells. C: Chondrocytes transfected with COX-2 or CXCR4 
gene reporter, were treated with 250 µl of a. PRP or n.a. PRP. The histograms indicate the 
absolute values for Firefly/Renilla luciferase activity ratios. Columns, mean of two 
independent experiments (2 patients) performed in triplicate; bars, S.E. **P<0.005 vs. 
untreated-gene reporter transfected cells.  
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Fig. 3. Expression of IkBα after HGF treatment. A: Chondrocytes were transfected with 
IkBα promoter and exposed to HGF. The histograms indicate the absolute values for 
Firefly/Renilla luciferase activity ratios. Columns, mean of three independent 
experiments performed in triplicate; bars, S.E. *P<0.05 vs. st cells. B: Western blot 
analysis carried out with total protein extracts from cells exposed or not to HGF. Anti-β-
actin antibody was used for normalization. The numbers at the bottom indicate the fold-
variations relative to the starvation value, considered as 1. The experiments have been 
repeated three times with similar results. C: Immunofluorescence images of chondrocytes 
treated with HGF or IL-1β and probed with anti-p65 and anti-IkBα antibodies. The nuclei 
were stained with DAPI (bleu). Merge I, p65/DAPI; merge II, IkBα/DAPI; merge III, 
p65/IkBα. The images, taken at X400 magnification, are representative of experiments 
performed in triplicate. 
 
Fig. 4. Role played by NF-kB-p50 subunit in the inhibitory response to TNF-α. A: The 
chondrocytes were treated with TNF-α, and 10 µg nuclear protein extracts were used for 
DNA binding of p50 or p65. The histograms indicate the fold-increase of DNA binding 
in TNF-α treated vs. untreated cells, considered as 1. Columns, mean of three 
independent experiments performed in triplicate; bars, S.E. *P<0.05 and **P<0.005 vs. 
st-untreated cells. B: Chondrocytes transfected with COX-2Luc or A20Luc, were treated 
with TNF-α or were co-transfected with p50 in combination or not with p65 expression 
vector. The histograms indicate the absolute values for Firefly/Renilla luciferase activity 
ratios. Columns, mean of three independent experiments performed in triplicate; bars, 
S.E. *P<0.05 and **P<0.005 vs st cells transfected with the gene reporter (COX-2Luc or 
A20Luc).  
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Fig. 5.  CXCR4 expression in U937 cells exposed to activated PRP (a. PRP) or in 
untreated control cells assessed by flow cytometric analysis. A: Starved U937 cells, 
treated overnight with a. PRP (500 µl), were stained with an isotype control antibody 
(grey area) or the monoclonal anti-CXCR4 antibody, and were analyzed by flow 
cytometry. Two independent experiments (2 patients) were performed, and the 
determinations were repeated three times with similar results. Representative images are 
shown. B: Columns show the percentage of positive cells, reacting with anti-CXCR4 
antibody, after subtraction of the aspecific (isotype-antibody reaction) area. The data are 
the mean ± S.E. of two independent experiments repeated three times. ***P<0.001 vs. 
control cells. 
 
Fig. 6. Activated PRP reduced the monocyte migration induced by CXCL12.  A: 
Chemotaxis assay of U937 cells was performed for 2 h towards starvation medium 
(control cells, C) or towards CXCL12, in the presence or the absence of activated PRP 
(250 µl) from two patients (P1 and P2). The data shown are the mean  ± S.E.  of two 
independent experiments performed in triplicate, using the cell count of ten fields/well. 
When the bars indicating S.E. are not shown, they are within the column. ***P < 0.001 
vs. control cells; ∆∆ P < 0.005 vs. CXCL12-exposed cells. Representative light 
microscopy images of Diff-Quik-stained U937 cells are shown (X400 magnification). (B) 
U937 cells were transfected with the gene reporter constructs for MCP-1  and RANTES, 
in the presence or the absence of activated PRP (250 µl) from two patients, or were 
treated with TNF-α and TGF-β1 alone or in combination. The histograms indicate the 
absolute values for Firefly/Renilla luciferase activity ratios. Columns: mean of 
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experiments carried out with PRP from 2 patients, and performed in triplicate; for TNF-α 
and TGF-β1 mean of two independent experiments performed in triplicate; bars, S.E. 
When the bars indicating S.E. are not shown, they are within the column. *P < 0.05 and 
**P < 0.005 vs. control cells;  ∆P<0.05 and ∆∆P < 0.005 vs. TNF-α-treated cells. 
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Table 1  
 
Concentration of HGF in non activated and activated PRP 
 
 
 
 
 
 
 
 
 
 
 
 
Number of patients = 5. *P<0.05;**P<0.005. 
 
 
Concentrations of TGF-β1 and PDGF in non activated and activated PRP 
 
 
 
 
 
 
 
 
 
 
Number of patients = 5. **P <0.005 
 
 
Cell count of platelets, monocytes and neutrophils in PRP 
 
Cell type 106 cells/ml 
 
Platelets 
 
Monocytes 
 
Neutrophils 
 
 
1,850 ± 320 
 
   2.5 ± 0.6 
 
   3.2 ± 0.9 
 
        Number of patients = 5. 
 
PRP HGF (ng/ml) Fold 
 increase 
    
 Non activated 
    
 Activated  1h  
 
 Activated 24h 
    
 
2.28 ± 0.22 
 
4.14 ± 0.39*      
 
  8.19 ± 0.79** 
 
 
 
1.8 
 
3.6 
PRP TGF-β1 (ng/ml) Fold 
increase
PDGF (ng/ml) Fold 
increase
 
Non activated 
 
Activated 1h 
 
Activated 24h 
 
 
12.42 ± 1.31 
 
    32.81 ± 4.55** 
 
    31.27 ± 4.03** 
 
 
 
2.6 
 
2.5 
 
3.15 ± 0.45 
 
  11.34 ± 1.95** 
 
10.71 ± 1.63** 
 
 
 
3.6 
 
3.4 
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